Mylan Wins Permanent Block of Apotex Generic Paxil Sales

Generic drugmaker Mylan Inc. (MYL) won a U.S. federal judge’s order to permanently block business partner GlaxoSmithKline Plc from supplying Apotex Inc. with marketable copies of the antidepressant Paxil CR.

The case dates to 2007, when Glaxo filed a suit accusing Mylan of infringing a Paxil patent, U.S. District Judge Joel Pisano in Trenton, New Jersey, said yesterday in granting an injunction. The parties settled, with Mylan buying a license to sell a generic version of the drug, the judge wrote.

When Glaxo granted a second license to Apotex in 2010, Mylan sued and lost. The U.S. Court of Appeals in Philadelphia reinstated a breach-of-contract claim in July 2013 and sent it back for trial, Pisano wrote.

On March 25, a jury found for Canonsburg, Pennsylvania-based Mylan, and awarded it $106.7 million in damages, finding “Glaxo (GSK)’s agreement with Apotex breached the license agreement,” Pisano said. Mylan requested the injunction after the trial.

Mary Anne Rhyne, a spokeswoman for London-based Glaxo, didn’t immediately return a call seeking comment on the ruling.

The case is Mylan Inc. v. SmithKline Beecham Corp., 10-cv-04809, U.S. District Court, District of New Jersey (Trenton).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at

To contact the editors responsible for this story: Michael Hytha at Andrew Dunn, David Glovin

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.